Congressmembers Langworthy, Schrier Introduce Bipartisan Bill to Lower Prescription Drug Costs by Expanding Access to Biosimilars
Food and Drug Administration's (FDA) biosimilar approval process, reduce unnecessary regulatory barriers, and help bring lower-cost … already requires extensive scientific evidence before approving a biosimilar, manufacturers are often expected to conduct additional clinical studies